MSCs and Exosomes Therapeutics: Lessons Learned and a Promising Future
Thursday, Sept. 28th, 2023 | 11 AM ET
Clinical research explored the use of mesenchymal stem cells (MSCs) to improve islet engraftment or suppress the immune response to allo-islets. The webinar will address the questions you may have about MSCs such as: what tissues contain MSCs and how are they isolated? How do they work? What is the status of MSCs as the primary or supplementary cell therapy? Kevin Hicok, an expert in this area, will review the development of MSC therapies and second-generation MSC secretome-derived therapeutics [aka exosomes, or extracellular vesicles (EVs)]. Secretome therapy appears to be the bright light at the end of the therapy development tunnel. In this webinar, he will highlight some challenges of bringing MSC cell therapies to the market and how the next-generation exosome-based therapeutics may overcome them. The application of these developments to islet transplantation will be noted during the webinar.
About the Presenter
Kevin Hicok has over 30 years of experience in the development of cell therapies to treat injury and disease. After obtaining his graduate degree in Cellular and Development Biology at the University of Minnesota, he spent 11 years at the Mayo Clinic in Rochester MN where he developed conditionally immortalize multi-potential MSC cell lines to understand their role in bone turnover and osteoporosis. In 2000, he entered the fledgling MSC therapy biotech industry and has since led R&D efforts at a number of pioneering MSC therapeutic companies, including Artecel Therapeutics, Osiris Therapeutics, Cytori, VetStem Biopharma, Gallant and Direct Biologics. Currently he is consulting and cofounding a new stealth start-up company.